BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DataCutoff//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DataCutoff · $MIRM readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by DataCutoff. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05050136-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:~VANTAGE readout (P2) · Mirum Pharmaceuticals\, Inc. $MIRM
DESCRIPTION:A Study to Evaluate Efficacy and Safety of an Investigational D
 rug Named Volixibat in Patients With Itching Caused by Primary Biliary Cho
 langitis\n\nPrimary completion date: 2027-01 (estimated) — month only\, 
 shown on the 1st\nOriginally planned: 2023-12 (+37.0 months)\nPhase 2 · I
 mmuno · Primary Biliary Cholangitis\, PBC\nEnrollment: 333 · Sites: 130\
 n\nPrimary completion = last participant's primary-endpoint data collected
 \; topline results usually follow weeks to months later. Sponsor-reported\
 , often an estimate. Not investment advice.\n\nhttps://datacutoff.com/rada
 r.html?nct=NCT05050136\nhttps://clinicaltrials.gov/study/NCT05050136
URL:https://datacutoff.com/radar.html?nct=NCT05050136
CATEGORIES:Immuno,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07200908-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Brelovitug 300 mg readout (P3) · Mirum Pharmaceuticals\, Inc. $MIR
 M
DESCRIPTION:A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the 
 Treatment of Chronic Hepatitis Delta Infection (AZURE-2)\n\nPrimary comple
 tion date: 2027-06-30 (estimated)\nPhase 3 · Infectious · Chronic Hepati
 tis D Infection\nEnrollment: 172 · Sites: 57\n\nPrimary completion = last
  participant's primary-endpoint data collected\; topline results usually f
 ollow weeks to months later. Sponsor-reported\, often an estimate. Not inv
 estment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT07200908\nhttp
 s://clinicaltrials.gov/study/NCT07200908
URL:https://datacutoff.com/radar.html?nct=NCT07200908
CATEGORIES:Infectious,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07454837-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Brelovitug (BJT-778) readout (P2/3) · Mirum Pharmaceuticals\, Inc.
  $MIRM
DESCRIPTION:Study to Evaluate Switching to Brelovitug for the Treatment of 
 CHD in Participants Receiving Bulevirtide\n\nPrimary completion date: 2027
 -08-31 (estimated)\nPhase 2/3 · Infectious · Chronic Hepatitis D\nEnroll
 ment: 120 · Sites: 46\n\nPrimary completion = last participant's primary-
 endpoint data collected\; topline results usually follow weeks to months l
 ater. Sponsor-reported\, often an estimate. Not investment advice.\n\nhttp
 s://datacutoff.com/radar.html?nct=NCT07454837\nhttps://clinicaltrials.gov/
 study/NCT07454837
URL:https://datacutoff.com/radar.html?nct=NCT07454837
CATEGORIES:Infectious,Phase 2/3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07209462-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:~Low dose of MRM-3379 readout (P2) · Mirum Pharmaceuticals\, Inc. 
 $MIRM
DESCRIPTION:Study of MRM-3379 in Male Participants With Fragile X Syndrome 
 (BLOOM)\n\nPrimary completion date: 2027-10 (estimated) — month only\, s
 hown on the 1st\nPhase 2 · Rare · Fragile X Syndrome\nEnrollment: 60 · 
 Sites: 18\n\nPrimary completion = last participant's primary-endpoint data
  collected\; topline results usually follow weeks to months later. Sponsor
 -reported\, often an estimate. Not investment advice.\n\nhttps://datacutof
 f.com/radar.html?nct=NCT07209462\nhttps://clinicaltrials.gov/study/NCT0720
 9462
URL:https://datacutoff.com/radar.html?nct=NCT07209462
CATEGORIES:Rare,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
